Abbott Laboratories
ABT
$103.09
+1.12%
Abbott Laboratories is a diversified healthcare company that manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic pharmaceuticals, with products spanning pacemakers, implantable cardioverter defibrillators, coronary stents, continuous glucose monitors, infant formula, and immunoassay and point-of-care diagnostic platforms. As one of the largest and longest-tenured medical device and diagnostics conglomerates in the world — publicly listed since 1949 with roughly 115,000 employees and approximately 60% of sales generated outside the United States — Abbott is best characterized as a scaled, defensive healthcare platform rather than a single-product story, deriving revenue across four distinct segments: Diagnostic Products, Medical Devices, Nutritional Products, and Established Pharmaceutical Products. The current investor narrative is dominated by a sharp divergence between the company's fundamental resilience and its stock performance: shares have fallen materially over the past year even as revenue grew roughly 7.8% year over year in the most recent quarter, with the April 2026 cut to full-year profit guidance overshadowing an otherwise solid Q1 earnings beat and becoming the central point of debate. Bulls point to the strategic acquisition of Exact Sciences, resilient medical device growth, and a 54-year track record of consecutive dividend increases as evidence of a compelling long-term entry point, while bears focus on margin pressure, the guidance reduction, and the stock's persistent underperformance relative to the broader market.…
ABT
Abbott Laboratories
$103.09
Related headlines
Investment Opinion: Should I buy ABT Today?
Rating: Hold with a bias toward accumulation on weakness. The core thesis is that Abbott's diversified healthcare platform, 7.78% revenue growth, and 17.9% upside to the $120.21 average analyst target offer a favorable risk/reward for patient investors, but near-term earnings uncertainty and technical weakness argue against aggressive buying until the guidance cut is fully digested. The consensus 'buy' rating (1.54 mean) and 24-analyst coverage provide validation, yet the stock's 23.14% one-year decline shows the market is pricing in real concerns.
Supporting evidence includes: (1) a forward PE of 16.81x, which is below the 18-22x range for large-cap medtech peers and less than half the trailing PE of 33.5x; (2) revenue growth of 7.78% year over year in Q1 2026, with Medical Devices and Diagnostics contributing $11.7 billion in combined quarterly sales; (3) a gross margin of 56.28% in Q1 2026, up from 52.56% a year earlier, showing pricing power; (4) $7.378 billion in trailing free cash flow supporting a 1.88% dividend yield and 54 consecutive years of increases; and (5) the stock trades at 4.94x sales and 19.51x EV/EBITDA, which is not distressed but reflects the recent de-rating. The implied upside to the average target is 17.9%, and even the low target of $103.00 is above the current price.
Key risks that could invalidate the thesis include: (1) a further reduction in 2026 guidance if margins do not stabilize, which would likely push the stock toward the $82-$85 support zone; (2) integration challenges with Exact Sciences that could dilute earnings or strain the balance sheet; and (3) a breakdown below the 52-week low of $81.97, which would confirm a deeper downtrend. The rating would upgrade to Buy if the stock reclaims $116-$117 and forward EPS estimates stabilize above $8.00, or downgrade to Sell if Q2 2026 revenue growth falls below 5% or net margin drops below 9%. Relative to its own history, the stock is undervalued on forward earnings and price-to-sales, but fairly valued on EV/EBITDA; relative to peers, it trades at a discount on forward PE. This is a value-oriented holding with a defensive tilt, not a momentum play.
Sign up to view all
ABT 12-Month Price Forecast
Abbott presents a classic value-versus-momentum dilemma: fundamentally, the company is growing revenue at a healthy clip, has a fortress balance sheet, and trades at a discount to peers on forward earnings, yet the stock is in a clear downtrend and recently cut guidance. The forward PE of 16.81x suggests the market is pricing in a successful earnings recovery, but the Q1 net margin of 9.65% shows that recovery is not yet visible. Analyst targets imply 17.9% upside, but the stock's failure to hold above $116-$117 indicates persistent selling pressure. I would upgrade to bullish if the stock reclaims $116 and forward EPS estimates stabilize above $8.00, and downgrade to bearish if it breaks below $82 or if Q2 revenue growth falls below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Abbott Laboratories's 12-month outlook, with a consensus price target around $120.26 and implied upside of +16.7% versus the current price.
Average Target
$120.26
0 analysts
Implied Upside
+16.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$103 - $135
Analyst target range
Wall Street coverage of Abbott is robust, with 24 analysts contributing to the consensus. The recommendation distribution leans bullish, with a consensus recommendation of "buy" and a recommendation mean of 1.54 (where 1.0 is a strong buy and 5.0 is a strong sell), indicating that the vast majority of covering analysts rate the stock a Buy or Overweight. The average price target of $120.21 implies approximately 17.9% upside from the current price of $101.95, a meaningful premium that suggests analysts view the recent selloff as overdone relative to fundamental value. The consensus is clearly bullish, though the stock's persistent underperformance raises the question of whether analysts are behind the curve on the guidance cut's implications.
The target range spans from a low of $103.00 to a high of $135.00, a spread of $32.00 or roughly 31% of the current price — a moderately wide range that signals meaningful disagreement about the company's trajectory. The high target of $135.00 implies roughly 32.4% upside and would require a full recovery toward the 52-week high of $137.49, assuming multiple expansion, successful integration of the Exact Sciences acquisition, and a return to mid-single-digit or better earnings growth. The low target of $103.00 implies just 1.0% upside and essentially prices in a scenario where the guidance cut proves conservative but no re-rating occurs, with margins remaining under pressure. Notably, the institutional ratings data shows a cluster of reiterations in April 2026 (Barclays, Piper Sandler, Evercore ISI, Stifel, Benchmark, RBC Capital, Oppenheimer) all maintaining Buy/Outperform/Overweight ratings, with no downgrades visible — suggesting analysts are holding the line on their constructive views despite the stock's weakness, which could be either conviction in the long-term story or a lag in adjusting to deteriorating near-term fundamentals.
Drowning in data?
Find the real signal!
Bulls vs Bears: ABT Investment Factors
The bear case currently has stronger near-term evidence: the guidance cut, margin compression, and technical breakdown are concrete and recent, while the bull case relies on mean reversion and long-term fundamentals. The most important tension is whether the Q1 margin decline is a temporary trough or the start of a sustained earnings downgrade cycle. If margins stabilize and the Exact Sciences deal accretes as planned, the forward PE of 16.81x and 17.9% analyst upside make a strong recovery case. However, until the stock reclaims $116-$117 and earnings estimates stop falling, the path of least resistance remains lower.
Bullish
- Deep analyst discount to fair value: The consensus average price target of $120.21 implies 17.9% upside from the current $101.95, with 24 analysts maintaining a 'buy' rating (recommendation mean 1.54). Even the lowest target of $103.00 is above the current price, suggesting the selloff has overshot fundamental value.
- Forward PE at a peer discount: The forward PE of 16.81x is well below the 18-22x range typical for large-cap medtech peers, and less than half the trailing PE of 33.5x. This discount reflects temporary earnings distortion from the 2024 tax gain, not a structural deterioration in profitability.
- Resilient top-line growth: Q1 2026 revenue grew 7.78% year over year to $11.164 billion, continuing a multi-quarter expansion from $10.377 billion in Q2 2024. Medical Devices ($5.539 billion) and Diagnostics ($6.200 billion) provide diversified, recurring revenue streams.
- Fortress balance sheet and dividend: Debt-to-equity of 0.289 and a current ratio of 1.576 provide ample financial flexibility, while the 1.88% dividend yield and 63.09% payout ratio are supported by $7.378 billion in trailing free cash flow. The company has raised its dividend for 54 consecutive years.
Bearish
- Guidance cut signals earnings risk: The April 2026 reduction to full-year profit guidance overshadowed a Q1 earnings beat, triggering an 8.08% one-month decline. This suggests management sees margin or demand headwinds that are not yet fully reflected in consensus estimates.
- Severe margin compression: Q1 2026 net margin fell to 9.65% from 15.50% in Q4 2025, and operating margin dropped to 16.50% from 19.64%. The 39% sequential decline in net income from $1.776 billion to $1.077 billion highlights deteriorating profitability conversion.
- Persistent underperformance: The stock is down 23.14% over one year and 17.91% year-to-date, versus the S&P 500's +16.22% and +12.08% returns. A relative strength of -39.36 over one year indicates deep investor skepticism that may not reverse quickly.
- Technical downtrend intact: At $101.95, the stock trades at just 36.8% of its 52-week range and remains below its 200-day moving average. The recent failure near $116-$117 (August highs) and a -39.57% max drawdown confirm the primary trend is still down.
ABT Technical Analysis
Abbott is in a sustained downtrend that has recently transitioned into a volatile recovery attempt. The stock is down 23.14% over the trailing twelve months and 17.91% year-to-date, a stark underperformance versus the S&P 500's +16.22% one-year and +12.08% YTD returns, producing a relative strength of -39.36 over one year. At the current price of $101.95, the stock sits at roughly 36.8% of its 52-week range (low of $81.97, high of $137.49), meaning it trades in the lower-middle portion of its annual band — closer to the lows than the highs, which historically signals either a value opportunity or an ongoing falling-knife dynamic depending on whether the fundamental deterioration has stabilized. The maximum drawdown of -39.57% underscores how severe the de-rating has been from the prior peak.
Short-term momentum is deteriorating even as the three-month picture remains positive, creating a notable divergence. The stock is down 8.08% over the past month versus the S&P 500's -1.06%, a relative strength of -7.02, while the three-month change is +15.62% and three-month relative strength is +12.58 — meaning the stock rallied strongly off its spring lows before rolling over again in recent weeks. This pattern — a strong three-month bounce followed by a weak one-month fade — suggests the recovery attempt from the $81.97 low has stalled and the stock is retesting support, with the six-month change of -5.63% and six-month relative strength of -21.03 confirming that the medium-term trend remains negative despite the spring rally.
Key technical levels are well defined: the 52-week low at $81.97 represents the critical support zone, while the 52-week high at $137.49 is the distant resistance that would need to be reclaimed to signal a true trend reversal. A breakdown below the $81.97 low would confirm the downtrend's continuation and likely trigger further selling, whereas a sustained breakout above the recent $116-$117 area (the August highs) would be the first meaningful sign of a bottoming pattern. With a beta of just 0.586, Abbott is roughly 41% less volatile than the broader market, which is consistent with its defensive healthcare profile and means position sizing can be larger for a given risk budget — but it also means the stock will likely lag in sharp market rallies, and the current weakness is company-specific rather than market-driven.
Beta
0.59
0.59x market volatility
Max Drawdown
-39.6%
Largest decline past year
52-Week Range
$82-$137
Price range past year
Annual Return
-22.9%
Cumulative gain past year
| Period | ABT Return | S&P 500 |
|---|---|---|
| 1m | -7.3% | -2.0% |
| 3m | +13.8% | +1.4% |
| 6m | -5.0% | +15.0% |
| 1y | -22.9% | +15.7% |
| ytd | -17.0% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABT Fundamental Analysis
Abbott's revenue trajectory remains solidly positive but is decelerating in terms of profitability conversion. Most recent quarterly revenue (Q1 2026, ended 2026-03-31) came in at $11.164 billion, up 7.78% year over year from $10.358 billion in Q1 2025, continuing a multi-quarter expansion that has seen revenue climb from $10.377 billion in Q2 2024 through $11.142 billion in Q2 2025 and $11.369 billion in Q3 2025. Segment data shows Medical Devices ($5.539 billion) and Diagnostic Products ($6.200 billion) as the dominant revenue drivers, with Nutritional Products ($2.017 billion) and Established Pharmaceuticals ($1.426 billion) providing diversification. The growth trend is respectable for a large-cap medtech conglomerate, but the market's negative reaction to the April 2026 guidance cut suggests investors are more focused on the forward earnings trajectory than on top-line resilience.
Profitability remains healthy in absolute terms but shows signs of compression at the margin. Q1 2026 net income was $1.077 billion on revenue of $11.164 billion, a net margin of 9.65% — down sharply from Q4 2025's $1.776 billion net income and 15.50% net margin, and below the 14.46% net margin in Q3 2025. Gross margin in Q1 2026 was 56.28%, a modest improvement from 52.56% in Q1 2025 but slightly below Q4 2025's 57.05%, while operating margin of 16.50% in Q1 2026 compares unfavorably to 19.64% in Q4 2025 and 18.09% in Q3 2025. The trailing twelve-month net margin of 14.72% and gross margin of 55.51% are solid for the medical device industry, but the sequential decline in net income from $1.776 billion to $1.077 billion quarter-over-quarter — a 39% drop — is the key concern driving the guidance reduction narrative.
Abbott's balance sheet is conservatively positioned with ample liquidity and modest leverage. Debt-to-equity stands at just 0.289, well below the 0.654 ratio reported in the Q1 2026 historical ratios snapshot, and the current ratio of 1.576 indicates comfortable short-term liquidity. Free cash flow on a trailing twelve-month basis is $7.378 billion, though Q1 2026 free cash flow of just $916 million was depressed by $399 million in capital expenditures and a $882 million working capital drag, and the quarter featured a massive $19.798 billion in acquisition-related outflows (likely tied to the Exact Sciences deal) funded partly by $18.475 billion in debt repayment activity. ROE of 12.51% and ROA of 5.33% are respectable but not exceptional, and with a dividend payout ratio of 63.09% and a 1.88% dividend yield, the company is returning substantial cash to shareholders while still investing heavily in M&A — a balanced but capital-intensive posture that bears watching if free cash flow generation does not accelerate.
Quarterly Revenue
$11.2B
2026-03
Revenue YoY Growth
+7.8%
YoY Comparison
Gross Margin
56.3%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABT Overvalued?
Because Abbott is solidly profitable — Q1 2026 net income of $1.077 billion and trailing twelve-month net margin of 14.72% — the PE ratio is the appropriate primary valuation metric. The stock trades at a trailing PE of 33.5x versus a forward PE of 16.81x, an extraordinarily wide gap that implies the market expects a dramatic earnings recovery; the forward multiple is based on consensus estimated EPS of $8.275 versus trailing EPS of roughly $3.04 (derived from the $101.95 price and 33.5x trailing PE), suggesting analysts anticipate earnings to more than double. This gap reflects the distortion from the 2024 tax-related gain that inflated trailing earnings, and investors should treat the forward PE as the more economically meaningful figure.
On a peer-relative basis, Abbott's valuation presents a mixed picture. The PS ratio of 4.94x and EV/Sales of 4.44x are moderate for a large-cap diversified medical device company, while the EV/EBITDA of 19.51x is on the higher end of the medtech range. The PB ratio of 4.20x and PCF ratio of 22.88x suggest the market is paying a premium for Abbott's cash generation and asset base. The forward PE of 16.81x is arguably attractive relative to the broader healthcare sector, where large-cap medtech peers often trade in the 18-22x forward earnings range, implying Abbott may be trading at a discount to peers on forward earnings — a discount that could be justified by the guidance cut and execution uncertainty, or could represent a value opportunity if the company delivers on its recovery trajectory.
Historically, Abbott's valuation has compressed meaningfully. The PE ratio has fallen from 41.4x in Q1 2026 and 30.7x in Q4 2025 to the current 33.5x trailing, while the PS ratio has declined from 22.38x in Q1 2025 and 21.25x in Q2 2025 to the current 4.94x — a dramatic compression that reflects both the stock price decline and revenue growth. The PB ratio of 4.20x is near the lower end of its historical range (which has ranged from roughly 3.45x to 6.93x over the past several years), and the dividend yield of 1.88% is at the higher end of its historical band (typically 0.43%-0.61% in the historical ratios data, though the current figure reflects the lower stock price). This combination — compressed multiples, elevated yield, and a forward PE well below trailing — suggests the market has already priced in significant pessimism, creating potential asymmetry if fundamentals stabilize.
PE
33.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 21x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.5x
Enterprise Value Multiple
Investment Risk Disclosure
Abbott's financial risk profile is moderate but deteriorating at the margin. The debt-to-equity ratio of 0.289 is conservative, and $7.378 billion in trailing free cash flow comfortably covers the 63.09% dividend payout. However, Q1 2026 free cash flow was only $916 million, depressed by a $882 million working capital drag and $399 million in capex, while the company absorbed $19.798 billion in acquisition-related outflows for Exact Sciences. If free cash flow does not rebound, the company may need to prioritize deleveraging over buybacks or dividend growth, potentially limiting shareholder returns. Additionally, the 39% sequential drop in net income to $1.077 billion and a net margin of 9.65% — down from 15.50% in Q4 2025 — highlight earnings volatility that could persist if cost pressures or integration expenses remain elevated.
Market and competitive risks are significant given Abbott's premium valuation on some metrics and its exposure to regulatory and reimbursement changes. The EV/EBITDA of 19.51x is above the medtech average, leaving little room for error if growth slows. The beta of 0.586 provides some insulation from broad market selloffs, but the stock's -39.36 relative strength over one year shows it is not immune to sector-specific de-rating. Competition in continuous glucose monitoring (from Dexcom and Medtronic) and diagnostics (from Roche and Siemens) could pressure pricing and market share. Recent news highlights the guidance cut as a key overhang, and while analysts have maintained Buy ratings, any further reduction in estimates could trigger downgrades and multiple compression.
The worst-case scenario involves a combination of stalled margin recovery, integration missteps with Exact Sciences, and a broader healthcare sector rotation away from defensive names. In this scenario, the stock could retest its 52-week low of $81.97, representing a 19.6% decline from the current $101.95. If the low target of $103.00 is breached and the bear case unfolds, a drop to the $82-$85 range is plausible, implying a loss of 16-20%. A more severe outcome, such as a recession that curbs medical device spending and delays elective procedures, could push the stock below $80, though the 54-year dividend track record and low beta would likely attract income investors and limit the downside. The maximum drawdown of -39.57% from the prior peak illustrates the potential magnitude if fundamentals deteriorate further.
FAQ
The most severe risk is earnings deterioration: Q1 2026 net margin fell to 9.65% from 15.50% in Q4 2025, and the April guidance cut suggests further pressure, which could drive the stock toward the 52-week low of $81.97. Second, integration risk from the Exact Sciences acquisition is significant, given $19.798 billion in acquisition-related outflows in Q1 2026 and the potential for dilution or synergy shortfalls. Third, competitive threats in continuous glucose monitoring and diagnostics could erode market share and pricing power, especially as peers like Dexcom and Medtronic innovate. Fourth, macro and regulatory risks, including reimbursement changes and a strong dollar (60% of sales are international), could pressure revenue and margins. The low beta of 0.586 mitigates broad market risk but does not protect against company-specific issues.
Our 12-month forecast assigns a 55% probability to the base case, with a target range of $110-$125, assuming revenue growth of 6-8% and net margin recovery to 12-13%. The bull case (25% probability) targets $125-$135, driven by successful Exact Sciences integration and a return to double-digit earnings growth. The bear case (20% probability) targets $82-$95, reflecting a continued margin decline and a retest of the 52-week low. The most likely scenario is the base case, where the stock grinds higher toward the analyst average target of $120.21 as earnings visibility improves. Key assumptions include no further guidance cuts and stable macro conditions; a break below $82 would invalidate the base case and shift probability toward the bear scenario.
Abbott appears undervalued on forward earnings but fairly valued on other metrics. The forward PE of 16.81x is below the 18-22x range for large-cap medtech peers, suggesting a discount, while the trailing PE of 33.5x is distorted by the 2024 tax gain and should be ignored. The PS ratio of 4.94x and EV/EBITDA of 19.51x are in line with or slightly above peers, indicating the market is not pricing in a deep discount. Relative to its own history, the PS ratio has compressed from over 20x in 2025 to 4.94x, and the PB ratio of 4.20x is near the low end of its historical range. The market appears to be pricing in a successful earnings recovery, as the forward PE implies EPS more than doubling to $8.275, but the guidance cut introduces uncertainty. Overall, the stock is modestly undervalued if the recovery materializes, but could be fairly valued if growth stalls.
From a risk/reward perspective, ABT offers a favorable setup for patient investors: the stock trades at $101.95, implying 17.9% upside to the average analyst target of $120.21, with a forward PE of 16.81x that is below the medtech peer range of 18-22x. The downside risk is quantifiable, with the 52-week low at $81.97 representing a 19.6% decline, but the 1.88% dividend yield and low beta of 0.586 provide some cushion. The biggest risk is that the April guidance cut signals a deeper earnings problem, which could push the stock toward the low target of $103 or below. For long-term investors with a 2-3 year horizon, the current price may represent a good entry point, but short-term traders should wait for a breakout above $116-$117 to confirm a trend reversal.
ABT is best suited for long-term investment, with a suggested minimum holding period of 2-3 years. The company's 54-year dividend growth streak, 1.88% yield, and low beta (0.586) make it an ideal core holding for income and defensive portfolios. Short-term trading is less attractive given the stock's -8.08% one-month return and the unresolved guidance cut, which creates near-term volatility. The forward PE of 16.81x and 17.9% analyst upside suggest that patient investors will be rewarded as margins recover, but the technical downtrend and -39.57% max drawdown indicate that timing the bottom is difficult. For those with a shorter horizon, waiting for a breakout above $116-$117 would reduce risk, but the dividend and valuation make a buy-and-hold approach viable for long-term investors.
